ENALKIREN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C35H56N6O6
Molecular Weight	656.8557
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC3CCCCC3)[C@@H](O)[C@@H](O)CC(C)C)C=C1

InChI

InChIKey=KQXVERRYBYGQJZ-WRPDIKACSA-N

InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)/t27-,28-,29-,30-,32+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800000369 | https://www.ncbi.nlm.nih.gov/pubmed/1705633 | https://www.ncbi.nlm.nih.gov/pubmed/2203852

Enalkiren (A-64662) is a potent, dipeptide renin inhibitor, mimics the transition state of the human renin substrate, angiotensinogen. The results of clinical trials with enalkiren suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension. In addition, it exerts intraocular pressure lowering pressure. Enalkiren development for the treatment of glaucoma, heart failure, hypertension has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
The power of visual imagery in synthesis planning. Stereocontrolled approaches to CGP-60536B, a potent renin inhibitor.	2002 Jun 14	12054962
Renin inhibition: what are the therapeutic opportunities?	2005 Mar	15703270
Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension.	2007	18200801
Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy.	2008	19337534
Purification and characterization of recombinant human renin for X-ray crystallization studies.	2008 Jun 26	18582379
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.	2009	19475781

Sample Use Guides

In Vivo Use Guide

Ascending doses from 0.001 to 1.0 mg/kg were evaluated

Route of Administration: Intravenous

Name

Type

Language

ENALKIREN

Official Name

English

L-HISTIDINAMIDE, N-(3-AMINO-3-METHYL-1-OXOBUTYL)-O-METHYL-L-TYROSYL-N-(1-(CYCLOHEXYLMETHYL)-2,3-DIHYDROXY-5-METHYLHEXYL)-, (1S-(1R*,2S*,3R*))-

Common Name

English

enalkiren [INN]

Common Name

English

ABBOTT-64662

Code

English

(.ALPHA.S)-.ALPHA.-((.ALPHA.S)-.ALPHA.-(3-AMINO-3-METHYLBUTYRAMIDO)-P-METHOXYHYDROCINNAMAMIDO)-N-((1S,2R,3S)-1-(CYCLOHEXYLMETHYL)-2,3-DIHYDROXY-5-METHYLHEXYL)IMIDAZOLE-4-PROPIONAMIDE

Common Name

English

L-HISTIDINAMIDE, N-(3-AMINO-3-METHYL-1-OXOBUTYL)-O-METHYL-L-TYROSYL-N-((1S,2R,3S)-1-(CYCLOHEXYLMETHYL)-2,3-DIHYDROXY-5-METHYLHEXYL)-

Systematic Name

English

A-64662

Code

English

ENALKIREN [USAN]

Common Name

English

ENALKIREN [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C270